CORRECTING and REPLACING Sucampo Pharmaceuticals Announces Webcast of its Presentation at the 2012 Credit Suisse Healthcare

  CORRECTING and REPLACING Sucampo Pharmaceuticals Announces Webcast of its
  Presentation at the 2012 Credit Suisse Healthcare Conference Sucampo Pharmaceuticals, Inc.

Business Wire

BETHESDA, Md. -- November 14, 2012

In the first graph, the date should read: Thursday, November 15 (sted
Wednesday, November 14).

The corrected release reads:


Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that it will
webcast its corporate presentation at the 2012 Credit Suisse Healthcare
Conference on Thursday, November 15, 2012, at 11:30 am Mountain, or 1:30 pm

The presentation will be webcast live and may be accessed from the Event
Calendar page of Sucampo’s website at A replay
of the webcast will also be available on the Company’s website for several
days after the live event. To ensure a timely connection, it is recommended
that users register at least 15 minutes prior to the scheduled webcast.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., a global pharmaceutical company, is focused on
innovative research, discovery, development and commercialization of
proprietary drugs based on prostones. The therapeutic potential of prostones,
which occur naturally in the human body as a result of enzymatic (15-PGDH)
transformation of certain fatty acids, was first identified by Ryuji Ueno,
M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals’ Chairman and Chief Executive
Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno,
Ph.D., founding Chief Executive Officer. For more information, please visit

Forward-Looking Statements

This press release contains “forward-looking statements” as that term is
defined in the Private Securities Litigation Reform Act of 1995. These
statements are based on management’s current expectations and involve risks
and uncertainties, which may cause results to differ materially from those set
forth in the statements. The forward-looking statements may include statements
regarding product development, product potential, future financial and
operating results, and other statements that are not historical facts. The
following factors, among others, could cause actual results to differ from
those set forth in the forward-looking statements: the impact of
pharmaceutical industry regulation and health care legislation; Sucampo’s
ability to accurately predict future market conditions; dependence on the
effectiveness of Sucampo’s patents and other protections for innovative
products; the risk of new and changing regulation and health policies in the
US and internationally and the exposure to litigation and/or regulatory

No forward-looking statement can be guaranteed and actual results may differ
materially from those projected. Sucampo undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events, or otherwise. Forward-looking statements in this presentation
should be evaluated together with the many uncertainties that affect Sucampo’s
business, particularly those mentioned in the risk factors and cautionary
statements in Sucampo’s Form 10-K for the year ended Dec. 31, 2011, which the
Company incorporates by reference.


Sucampo Pharmaceuticals, Inc.
Silvia Taylor, +1-240-223-3718
Kate de Santis, +1-240-223-3834
Press spacebar to pause and continue. Press esc to stop.